| An immune atlas of clear cell renal cell carcinoma S Chevrier, JH Levine, VRT Zanotelli, K Silina, D Schulz, M Bacac, ... Cell 169 (4), 736-749. e18, 2017 | 969 | 2017 |
| Metastatic cancer cell M Bacac, I Stamenkovic Annu. Rev. Pathol. Mech. Dis. 3 (1), 221-247, 2008 | 454 | 2008 |
| Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ... Cancer immunology research 3 (12), 1344-1355, 2015 | 415 | 2015 |
| Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models S Herter, F Herting, O Mundigl, I Waldhauer, T Weinzierl, T Fauti, G Muth, ... Molecular cancer therapeutics 12 (10), 2031-2042, 2013 | 395 | 2013 |
| A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ... Clinical Cancer Research 22 (13), 3286-3297, 2016 | 379 | 2016 |
| Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ... Journal of Clinical Oncology 39 (18), 1959-1970, 2021 | 370 | 2021 |
| Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment A Seckinger, JA Delgado, S Moser, L Moreno, B Neuber, A Grab, S Lipp, ... Cancer cell 31 (3), 396-410, 2017 | 329 | 2017 |
| Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and … C Klein, I Waldhauer, VG Nicolini, A Freimoser-Grundschober, T Nayak, ... Oncoimmunology 6 (3), e1277306, 2017 | 263 | 2017 |
| Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy C Claus, C Ferrara, W Xu, J Sam, S Lang, F Uhlenbrock, R Albrecht, ... Science translational medicine 11 (496), eaav5989, 2019 | 244 | 2019 |
| The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation M Bacac, ACG Hotze, K van der Schilden, JG Haasnoot, S Pacor, ... Journal of inorganic biochemistry 98 (2), 402-412, 2004 | 221 | 2004 |
| CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies M Bacac, S Colombetti, S Herter, J Sam, M Perro, S Chen, R Bianchi, ... Clinical Cancer Research 24 (19), 4785-4797, 2018 | 213 | 2018 |
| Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity S Herter, MC Birk, C Klein, C Gerdes, P Umana, M Bacac The Journal of Immunology 192 (5), 2252-2260, 2014 | 185 | 2014 |
| Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer A Planche, M Bacac, P Provero, C Fusco, M Delorenzi, JC Stehle, ... PloS one 6 (5), e18640, 2011 | 177 | 2011 |
| PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells L Codarri Deak, V Nicolini, M Hashimoto, M Karagianni, PC Schwalie, ... Nature 610 (7930), 161-172, 2022 | 159 | 2022 |
| Engineering therapeutic bispecific antibodies using CrossMab technology C Klein, W Schaefer, JT Regula, C Dumontet, U Brinkmann, M Bacac, ... Methods 154, 21-31, 2019 | 146 | 2019 |
| A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents S Herter, L Morra, R Schlenker, J Sulcova, L Fahrni, I Waldhauer, ... Cancer Immunology, Immunotherapy 66, 129-140, 2017 | 143 | 2017 |
| CEA TCB: a novel head-to-tail 2: 1 T cell bispecific antibody for treatment of CEA-positive solid tumors M Bacac, C Klein, P Umana Oncoimmunology 5 (8), e1203498, 2016 | 135 | 2016 |
| New cytotoxic and water-soluble bis (2-phenylazopyridine) ruthenium (II) complexes ACG Hotze, M Bacac, AH Velders, BAJ Jansen, H Kooijman, AL Spek, ... Journal of medicinal chemistry 46 (9), 1743-1750, 2003 | 119 | 2003 |
| The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support A Irmisch, X Bonilla, S Chevrier, KV Lehmann, F Singer, NC Toussaint, ... Cancer Cell 39 (3), 288-293, 2021 | 116 | 2021 |
| Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru (L) 2 Cl 2](L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru (azpy) 2 Cl 2] ACG Hotze, SE Caspers, D de Vos, H Kooijman, AL Spek, A Flamigni, ... JBIC Journal of Biological Inorganic Chemistry 9, 354-364, 2004 | 109 | 2004 |